周三，GE Vernova(GEV.US)盘前大涨超10%，报689.07美元。消息面上，此前该公司宣布将股息翻倍， 提高股票回购授权，并在提高了盈利预期。这家涡轮机制造商将季度股息提高至每股0.50美元，并将股 票回购授权从60亿美元提高至100亿美元，这主要得益于大量且不断增长的积压订单、强劲的利润率以 及更优惠的招聘价格。 GE Vernova还发布了2026年的初步业绩指引，预计收入为410亿至420亿美元，自由现金流为45亿至50亿 美元，同时将本年度的自由现金流预期从之前的30亿至35亿美元上调至35亿至40亿美元，并维持对360 亿至370亿美元的收入预期，且倾向于区间顶端。GE Vernova首席执行官Scott Strazik表示："公司正处于 创造巨大价值的早期阶段，未来财务状况将更加稳健。" ...

Dollar General Corporation (NYSE:DG) reported better-than-expected third-quarter fiscal 2025 results and raised its full-year guidance on Thursday.The discount retailer posted net sales of $10.65 billion, almost in line with the consensus estimate of $10.64 billion. Earnings came in at $1.28 per share, topping the Street’s estimate of 95 cents.On Thursday, Dollar General said it is raising its financial expectations for 2025, primarily to reflect its outperformance in the third quarter, as well as its impro ...

Key Takeaways SAIC posted Q3 EPS of $2.58 and $1.87B in revenues, beating estimates despite Y/Y declines.Net bookings hit $2.2B with a 1.2 book-to-bill ratio and a $23.8B backlog at quarter's end.FY26 guidance was raised, including higher revenue, EBITDA and EPS expectations.Science Applications International ((SAIC) delivered its third-quarter fiscal 2026 results, wherein the company reported non-GAAP earnings of $2.58 per share, surpassing the Zacks Consensus Estimate of $2.07 by 24.6%. However, the botto ...

Core Insights - Macy's exceeded Wall Street expectations in its recent quarterly report, indicating that consumer spending remains strong despite economic concerns [1] - The company raised its earnings guidance for the fiscal year, reflecting confidence in continued consumer demand [2] Financial Performance - Macy's reported third-quarter revenue of $4.7 billion, surpassing the market expectation of $4.56 billion [1] - Adjusted earnings per share were $0.09, significantly better than the analyst forecast of -$0.13 [1] - Comparable sales increased by 3.2%, exceeding the company's previous guidance [1] Strategic Outlook - The company raised its full-year adjusted earnings guidance to a maximum of $2.20 per share, up from a previous maximum of $2.05 [1] - Sales guidance was also increased to a range of $21.5 billion to $21.6 billion, higher than prior estimates [1][2] Market Position and Challenges - Despite strong performance, Macy's stock fell over 6% in pre-market trading, influenced by positive reports from other retailers [1] - The company faces challenges in regaining market share lost to discount retailers and e-commerce platforms since 2012 [2] - Macy's plans to close approximately 150 underperforming stores by 2026 [2] Consumer Trends - Management expects consumer spending momentum to continue, particularly during Black Friday and Cyber Monday [2] - Analysts noted that Macy's is gaining market share from competitors like Saks Global, especially in women's apparel [3]

Investment Rating - The industry investment rating is "Positive" and maintained [6] Core Insights - In FY2025Q3 (July 1, 2025 - September 30, 2025), Amer Sports achieved revenue of $1.76 billion, a year-on-year increase of 30% (28% at constant exchange rates), exceeding Bloomberg consensus expectations of $1.72 billion. The gross margin increased by 1.6 percentage points to 56.8%, primarily driven by channel, regional, and product mix optimization. Adjusted EBITDA rose by 38% to $350 million, with an adjusted EBITDA margin of 20.1%, up 1.2 percentage points year-on-year. Net profit attributable to shareholders surged by 156% to $140 million, with a net profit margin of 8.1%, an increase of 4.0 percentage points year-on-year [2][4][5]. Revenue Breakdown - Revenue growth was strong across all segments: 1. By product: Technical Apparel/Outdoor Performance/Ball & Racquet Sports revenues increased by 31%/36%/16% to $680 million/$720 million/$350 million, respectively, with constant exchange rates showing similar growth [5]. 2. By channel: Direct-to-Consumer (DTC) and wholesale revenues grew by 51% and 18% to $720 million and $1.03 billion, respectively, maintaining high growth across channels [5]. 3. By region: Revenues in the Americas/EMEA/Asia-Pacific/Greater China increased by 18%/23%/54%/47% to $570 million/$530 million/$190 million/$460 million, with all regions accelerating growth [5]. Inventory and Guidance - As of FY2025Q3, the company's inventory amounted to $1.71 billion, a year-on-year increase of 28%, with inventory levels remaining moderately high. The growth in inventory was mainly due to increases in Arcteryx inventory and exchange rate effects, with expectations for inventory growth to normalize by the second half of 2026 [10]. - The company raised its full-year guidance, projecting FY2025 revenue growth of 23% to 24% (previously 20% to 21%). Specific segment forecasts include Technical Apparel at 26% to 27%, Outdoor Performance at 28% to 29%, and Ball & Racquet Sports at 10% to 11%. The expected FY2025 gross margin is approximately 58% (previously 57.5%), with operating profit margins between 12.5% and 12.7% (previously 11.8% to 12.2%). EPS is projected to be between $0.88 and $0.92 (previously $0.77 to $0.82) [10].

Core Insights - Best Buy reported Q3 FY2026 revenue of $9.67 billion, exceeding market expectations of $9.58 billion, with a net profit of $140 million and adjusted EPS of $1.40, surpassing the forecast of $1.30 [1][2] - Same-store sales increased by 2.7%, outperforming the analyst average estimate of 1.62% [1] - The company raised its full-year revenue and profit guidance based on strong holiday season demand, driven by significant discounts on consumer electronics [1] Financial Performance - Domestic revenue reached $8.88 billion, a 2.1% year-over-year increase, primarily driven by a 2.4% rise in same-store sales [1] - International revenue was $794 million, up 6.1% year-over-year, supported by a 6.3% increase in same-store sales, although currency fluctuations negatively impacted results [1] - Online sales in the domestic market amounted to $2.82 billion, a 3.5% year-over-year increase, accounting for 31.8% of total domestic revenue [1] Product Performance - Computers and tablets contributed approximately one-third of total sales, benefiting from consumer upgrades and replacement needs stemming from the pandemic [2] - The gaming segment performed well, particularly due to the launch of Nintendo Switch 2 earlier this year [2] - Sales declines in home theater and appliance categories partially offset overall growth [2] Future Outlook - The company adjusted its FY2026 guidance, expecting same-store sales growth of 0.5% to 1.2%, up from a previous range of -1% to +1% [2] - Full-year revenue guidance was raised to a range of $41.65 billion to $41.95 billion, from the previous $41.1 billion to $41.9 billion [2] - Adjusted EPS expectations were narrowed to $6.25 to $6.35, compared to the prior range of $6.15 to $6.30 [2] Market Reaction - Following the earnings report, Best Buy's stock initially rose over 3% in pre-market trading but later declined by 1.08%, trading at $74.80 per share [3]

Core Viewpoint - ZIM reported a significant decline in financial performance for Q3 2025, with revenue and net profit dropping sharply compared to the previous year, reflecting challenges in the shipping industry due to geopolitical factors and fluctuating tariff policies [1][3][13]. Financial Performance Summary - In Q3 2025, ZIM's revenue reached $1.778 billion, a decrease of 35.7% year-on-year [3][4]. - The net profit for the same period was $123 million, down 89.1% compared to Q3 2024 [3][4]. - The average freight rate per container fell to $1,602, a decline of 35.4% year-on-year [3][4]. - The total container volume handled was 926,000 TEU, representing a 4.5% decrease from the previous year [3][4]. - EBITDA for Q3 2025 was $593 million, down 61.3% year-on-year [3][4]. Year-to-Date Performance - For the first nine months of 2025, ZIM's container volume was 2.765 million TEU, a slight decrease of 0.1% year-on-year [5][6]. - Revenue for the first nine months was $5.419 billion, down 13.4% compared to the same period in 2024 [5][6]. - Net profit for the first nine months was $443 million, a decrease of 72.2% year-on-year [5][6]. Market Trends and Insights - The most significant decline in container volume was observed in the Asia routes, which dropped by 4.1% to 187,000 TEU [8]. - The Pacific routes saw a slight increase of 1.7%, reaching 421,000 TEU [8]. - ZIM's free cash flow for Q3 2025 was $574 million, down 60.5% year-on-year [3][4]. Future Outlook - ZIM has raised its full-year guidance for 2025, expecting adjusted EBITDA to be between $2 billion and $2.2 billion, and adjusted EBIT to be between $700 million and $900 million [10][13]. - The CEO emphasized the company's resilience in a volatile market and the focus on sustainable and profitable growth strategies [13]. Competitive Position - ZIM ranks 10th among global shipping companies, operating 116 container ships with a total capacity of 704,000 TEU, of which 14 are owned and 102 are chartered [20].

Core Insights - BeiGene (ONC.US) shares rose over 3% to $332.26 following a strong quarterly earnings report [1] Financial Performance - In Q3, BeiGene's revenue surpassed 10 billion yuan, reaching 10.077 billion yuan, a year-on-year increase of 41.1% [1] - Product revenue continued to grow rapidly, achieving 9.954 billion yuan, up 40.6% year-on-year [1] - For the first three quarters of 2025, BeiGene's revenue reached 27.595 billion yuan, a 44.2% increase compared to the previous year [1] - The company's product revenue for the same period was 27.314 billion yuan, reflecting a 43.9% year-on-year growth [1] - Net profit attributable to shareholders was 1.139 billion yuan, driven by significant product revenue growth and improved cost management [1] Guidance and Adjustments - Due to strong Q3 performance, BeiGene raised its full-year revenue guidance for 2025, now expecting revenue between 36.2 billion and 38.1 billion yuan, up from a previous range of 35.8 billion to 38.1 billion yuan [1] - The revenue growth adjustment is primarily attributed to the leading position of Brukinsa (Zebutinib) in the U.S. market and its ongoing expansion in Europe and other key global markets [1] Cost Management - Research and development expenses, along with selling and administrative expenses, are expected to narrow to between 29 billion and 30.9 billion yuan, reflecting prudent investment strategies that enhance revenue and pipeline growth [1]

Core Insights - MongoDB (MDB.US) experienced a pre-market surge of over 9% and opened with a gain of more than 2.5%, trading at $369.3 [1] - The company announced a significant management change, appointing CJ Desai, a former executive from ServiceNow (NOW.US), as the new President and CEO, succeeding Dev Ittycheria [1] - MongoDB raised its guidance for the third quarter of fiscal year 2026, expecting revenue and earnings to exceed previous forecasts [1]

Core Insights - GSK reported strong third-quarter results with sales of $11.53 billion, an 8% increase at constant currency, surpassing analyst expectations of $11.16 billion [1] - Core earnings rose 15% at constant currency to $1.48 per share, exceeding the consensus forecast of $1.26 [1] Sales Performance - Vaccine sales increased by 1% to 2.68 billion pounds, driven by strong demand for Shingrix and Arexvy, despite lower sales in Established and Influenza vaccines [2] - Arexvy sales reached 251 million pounds, up 34%, while Meningitis vaccine sales increased 4% to 541 million pounds [3] - Shingrix sales were 830 million pounds, up 12%, and Specialty Medicines sales grew by 15% to 3.41 billion pounds, reflecting strong performance across various therapeutic areas [3] Guidance Update - GSK raised its full-year 2025 guidance, expecting sales growth of 6% to 7%, up from the previous 3% to 5% range [6] - Core operating profit is anticipated to grow between 9% to 11%, and core earnings per share are expected to increase by 10% to 12% [6] - Specialty Medicine sales are projected to increase at a mid-teens percentage, an upgrade from the prior low teens guidance [6] Market Response - Following the positive earnings report and upgraded guidance, GSK stock rose by 2.56% to $44.82 in premarket trading [7] Tariff Considerations - GSK acknowledged the ongoing U.S. investigation regarding the impact of pharmaceutical imports on national security and indicated potential European tariffs of 15% [5] - The company is prepared to address the financial implications of these tariffs with identified mitigation options [5]